MEDICINE REGULATION REGULATORY DEPARTMENTS GOOD REGULATORY PRACTICE

MEDICINE REGULATIONREGULATORY DEPARTMENTS

GOOD REGULATORY PRACTICE

SAAPRA 1 June 2012

OVERVIEW

Development of Legislation Medicines Regulation and RegulatorsRegulatory Affairs Department (RAD)Good Regulatory Practice (GRP)

Development of Medicines Legislation

Typically medicine regulations have been developed ‘after the fact’

Triggered by unwanted and sometimes disastrous events

Information and knowledge on the use of medicines increases exponentially

Result - Medicines legislation proliferates

Development of Legislation

USA 1846 – 1848 Mexican-American War American troops supplied with substandard

medicines 1848 – Import Drug Act passed 1901 – concern over unsanitary condition in meat

packing industry and also quality of medicines Medicines legislation outgrowth of food legislation


1902 – 12 children died from contaminated diphtheria toxin in St Louis

Result - Biologics Act of 1902 Demanded licensing of biological products and

facilities 1902 – 1907 Study on safety of food additives with

human volunteers Led to - 1906 Pure Food and Drugs Act First federal drugs law


Prohibited mislabelling and adulteration of medicinal products and

Introduced USP and NF as official standards

Legal system still allowed for unacceptable bizarre practices - false therapeutic claims

1912 - US vs Johnson case – promoters of “Dr. Johnson’s Mild Combination Treatment for Cancer” challenged

1912 Act amended –prohibited labelling with false therapeutic claims


1937 – Massengill Company place throat lozenge on market

Sulfanilamide dissolved in diethylene glycol (common car antifreeze agent)

107 people died (mostly children) Legislators acted rigorously to prevent reoccurrence 1938 – Food, Drug and Cosmetic Act passed Medicine could only be marketed after 60 days if no FDA

objections


Required proof of safety and efficacy 1951 – another amendment to Act Divided products into OTC and prescription requiring

professional supervision 1962 amendments made proof of efficacy mandatory Introduced GMP


Further amendments over 20 years such as

- 1983 Orphan Drugs Act – for marketing and commercialisation of medicines to treat rare diseases

- 1990 Nutrition and Labelling Act

- 1984 Drug Price Competition and Patent Term Restoration Act

- 1996 Generic Drug Enforcement Act


1988 Prescription Drug Marketing Act To ensure that medicines purchased by consumers

are safe and effective, and To avoid the unacceptable risk to American

consumers from counterfeit, adulterated, misbranded, subpotent, or expired drugs.

Additionally Guidance documents to be taken into account by industry

Other reform bills constantly under consideration


EUROPEAN UNION (EU) Germany and other countries originally focussed on

pharmacies only No Marketing Authorisation required for industrially

produced medicines 1961 registration introduced to determine what was

on market – notification process only In Germany 55 000 medicinal products on market at

time


Beginning 1960s sleeping pill Contergan (thalidomide) caused birth defects

Taken by mothers in early

stages of pregnancy Children born without arms -

hands starting at the shoulders Called ‘flipper babies’


An estimated 10 000 children were affected in Europe

1968 appetite suppressant Menocil (aminorex) caused many deaths – withdrawn from market

Led to implementation of medicines legislation in UK and other EU member states

Today legislation in EU member states mirrors EU Directive


SOUTH AFRICA 1965 Medicines and Related Substances Control Act

published and first medicines called up in 1968 2002 Medicines and Related Substances Act

amended making provision for inter alia licensing of manufacturers, wholesalers, distributors, etc.

2008 Amendment Act 72 introduced SAHPRA Latest draft amendment makes provision for the

structures required for the new juristic body

International Conference on Harmonisation(ICH)

ICH began to take place in 1989 Project of both Regulatory Bodies and

pharmaceutical industry from EU, Japan and United States

Harmonisation the major factor Goal - to expedite development and approval

processes for medicinal products Does not compromise safeguards on Q/S/E

World Health Organisation (WHO)

An intergovernmental organisation 166 member states within the Charter of the United Nations Activities include support for ministries of health concerning

development of methods for assessing quality, effectiveness and efficiency

Publications cover:

- essential drugs

- drug policies

- quality control

- ethical guidelines

- safety assessment, drug research and development and

- laboratories

Medicines Regulation and Regulators

Medicine legislation makes provision for Regulatory Authorities or Bodies

Have developed and continue to develop legislation This had and continues to have a significant effect

on pharmaceutical industry

Medicines Regulation and Regulators

Common misunderstanding – that Regulators register our medicines

They keep medicines off the market unless the applicant can prove quality, safety and efficacy

Ensure compliance with legislation Control the use and minimise the abuse of medicines Re-evaluate the medicines on the market

Regulatory Affairs Departments (RAD)

Why have companies established Regulatory Affairs Departments ?

Simple answer – because there are regulations and regulators

To understand and fulfil regulators’ needs as environment has become more and more complex


Mistakes cost a lot of money Worst mistake – calling in RA after plans have been finalised Pitfalls of product development:

- Not involving RA in plans

- Suppressing critics in the company – they are valuable in identifying problems

- Hiding critical issues chances good reviewer will spot them

- Telling all you know – leads to confusion


- Trying to make it perfect – a lot of time will be lost

- Doing all the studies as early as possible e.g. marketing studies

- Using in-house methods to structure the documentation – adapt to Regulator’s structure

Regulatory Affairs (RA)

RA is usually recognised as having three basic functions:

- The outlet of the company to Regulatory Bodies

- The interpreter of regulations to companies

- The influencer of new regulations Makes RA the interface between companies and Regulatory

Bodies and Key player in the product development and maintenance

process

Activities of the Regulatory Affairs Department (RAD)

Activities depend on each company’s structure and organisation

Start at the initial development of medicinal products Continue through until the launch of the product Steer and maintain an application through the legislative

framework - allows a Regulatory Authority to reach a scientific decision

Once launched, the RAD fully involved in Marketing Authorisation (MA) maintenance and post-marketing activities

Activities of the RAD

Product Development

RAD should be involved in the creation and evaluation of all aspects of research and development plansAdvise departmental heads and project managers on the requirements and any upcoming legal changes with potential impact for registrationRAD should give advice for optimising development plans By an accurate interpretation of the requirements of the existing guidelinesIdeally should be done within the scope of a Regulatory Strategy Document


Product Development

Ideally RAD should be able to liaise with Regulatory Authorities on any scientific aspect of:

– future Marketing Authorisation (MA) – dossier and co-ordinating with the other departments– the briefing document including the questions and company’s positions

On our wish list!


New RegistrationsRAD responsiblities:

- proposing the best registration strategy

- taking into account the possible registration procedures

- the impact of intellectual property rights

- the peculiarities of the product

- the scientific content of the different part of the dossierRAD preparation of Regulatory Strategy Document (RSD)

- containing all the essential global regulatory aspects of product development

- including scientific advice

- meeting with the Regulatory Authority


New RegistrationsRAD – ensure all activities related to obtaining registration comply with existing legislation i.e.

– laws, regulations, directives and guidelines– need to be proactive

RAD - should establish ethical, practical, technical and regulatory standards:

- laid down in policies and SOPs

- specify the responsibility of each staff member involved

- describe the process

- ensure content of dossiers in compliance with existing legislation and standard needed to obtain registration of the

product


New RegistrationsRAD responsiblities:

– writing, co-writing, editing and/or authorising all documentsfor use in registration dossiers or communication with the Authority e.g. manuscripts, expert reports, method of use, standard advice for patients and labels

– should strive for world-wide implementation of harmonised prescribing information

– should be responsible for the accurate planning and co-ordination of compiling the dossiers

– Take into account the possibilities for electronic submission of the dossier or parts of it especially in terms of submission of eCTDs


New Registrations– Ensuring administrative validation– Chasing up the dossier throughout the assessment and– Anticipating the possible questions from the Regulatory Authority

in order to optimise the timing, quality of the answer and Marketing Authorisation (MA) approval and package insert (PI) wording

Queries from the RA should be answered in a consistent manner and within the time limits set by the agency when indicated, according to internal guidelinesStatus reports should be issued regularly in order to provide information on the world-wide registration situation


Registrations– submission strategies (timing, responsibilities, free sale certificates

and answers to the Authority, questions, intellectual property– dossier updates (variations and safety)– dossier renewals– Periodic Safety Update Reports (PSURs) planning and a

contingency plan– must address the proposed labelling with Marketing and Sales– the impact on discussion with pricing and reimbursement

authorities


Maintenance of Existing Registrations

All existing registrations should be carefully maintained and regularly updated to reflect the current standards and knowledge

Variations and change control:– Management of change control forms are an important element of

GRP - Such changes include:o Product data or specifications o Manufacturing of analytic methodso Facilities or suppliers as well as line extensionso Additional indications, etc.

All such changes have to be communicated to the RA in accordance with the respective legal requirements affected



Queries raised by the RA to ensure regulatory compliance RAD and quality assurance department should liaise closely on all

aspects affecting variations and change control Responsibility of RAD, Responsible Pharmacist and QA (Quality

Assurance) to ensure manufacturing and QC (Quality Control) comply at all times with the registration dossier

RAD should assure regulatory compliance by the manufacturer, packager and marketing department


Maintenance of Existing Registrations Changes to PI and/or PIL

- Changes might be initiated by marketing or medical department- Can also be requested for new safety data- RAD and medical / pharmacovigilance c liaise closely for the preparation and timely implementation once the revised wording is approved

RAD in close collaboration with the Drug Safety department and a Qualified Person for Pharmacovigilance- Do PSURs planning on a yearly basis for each product- Collect all the information needed for their submission, taking into consideration post-approval commitment or follow-up measures



It is the duty of RAD

to ensure activities related to post marketing studies are carried out in compliance with and reported according to, existing legislation.

to inform the Regulatory Authorities of any pharmacovigilance issue and to implement and file the necessary data into the official documents

this will be done in close co-operation with the medical department and Qualified Person for Pharmacovigilance


Regulatory intelligence – Objective 1

RAD should – have a system in place to ensure the tracking of all the versions, either

approved or a draft for comment, of regulations guidelines and concepts papers

on an on-going basis review relevant world-wide legislation, guidelines, discussion papers, codes of conduct, etc.

interpret the scope and possible consequences arising from such legislation and codes and inform the company accordingly(may affect the activities of the company)

ensure and co-ordinate the necessary activities arising from changes to ensure that compliance with regulations will be met.


REGULATORY INTELLIGENCE - Objective 2

RAD should –

comment on new draft guidelines / draft legislation and take an active role in participating in the outcome of final regulatory comments.

for this purpose preferably join pharmaceutical associations to represent the needs of pharmaceutical industry on a higher level.

Good Regulatory Practice (GRP)

Problem today: Insufficient quality submissions to the Regulatory Authority Industry and Regulator perceive each other as opponents

rather than partners We are like opposite sides of the

same coin -neither side detracts from the

value of the coin but rather together give it

its character and identity.


Present system based on mutual mistrust Involves high cost i.t.o. time, manpower, rejects on both sides Quality cannot be added by regulations, guidelines, etc. Without any real dossier quality improvement timelines cannot

improve


Could GRP be the solution to the problem?


What is GRP?

Establishment of a quality system Involves both industry and Regulator About trying to achieve quality by less rather than more control About producing quality in the first place Based on sound science, coupled with organisational ability


What are the goals of GRP?

Efficiency: quick and qualified decisions on Q/S/E of products Effectiveness/productivity: effective use of resources, cost-

effectiveness Results: achieve and preserve an image of high standing

Good Regulatory Practice

What are the advantages of GRP?

Quality medicines available to patients in timely fashion Because global picture is seen and Entire process is designed to produce quality

Good Regulatory Practice

How?

Decide on goals What must be done by whom and how Write it down Adhere to it Watch the results and if necessary modify the system

Good Regulatory Practice(GRP)

A pre-requisite to GRP - the communication of all relevant information, including its evaluation and relevance for the existing product, to ALL interested parties within the organisation

Pivotal to GRP is the need to keep abreast of world-wide legislation including potential changes and

The interpretation of possible consequences in the event of failure to meet requirements

Good Regulatory Practice(GRP)

• The involvement of GRP in the concept of Total Quality Management (TQM) is essential from initial development phase of the product and continues for its entire life

• Efficient RAD organisation and working methods are mandatory

• RAD skills for communication and communicating information to other departments - a key parameter to ensure compliance with regulatory requirements


– Implementation of GRP essentially contributes towards continuous Total Quality Assessment of all aspects of regulatory affairs and is

– The essential link between each discipline in Total Quality Management

– Increasing complexity of regulatory requirements especially as RADs operate numerous interfaces within a pharmaceutical company


GRP Guidelines define the role and position of the RAD within the organisation

Appropriate and effective management of the regulatory process is mandatory for:

– Bringing a medicinal product to the market and keeping it there

– In compliance with legal, scientific, ethical and administrative requirements

– To ensure the compliance of the relevant company’s activities to the local and global regulations in terms of official and company regulations

PERSONNEL

There should be sufficient personnel at all levels within the organisation with the: AbilityEducationTrainingExperience and Appropriate professional skills to perform the tasks assigned to themAll personnel should be trained regularly in their skills to ensure they possess sufficient skill and knowledge of the procedures and policies of the organisationIdeally, all graduate personnel should have a multidisciplinary background

PERSONNEL

Ideally, all graduate personnel should have:– multidisciplinary background– scientific expertise– communication and negotiation skills– regulatory knowledge– planning capacity – be able to work in teams– to organize multidimensional projects– to work in a multidimensional manner

Standard operating procedures should be designed to deal with communication and flow of information

PERSONNEL

The responsibilities of the Responsible Pharmacist (RP) and the Qualified Person for Pharmacovigilance (QPPV) in relation to the RAD should be clearly defined

These responsibilities should be explained and written into the job description for each person together with any training and education required on product registration

Key personnel in responsible positions should be accountable for: – authorizing procedures and tasks and– having adequate supporting staff– persons should be designated to deputise for them in their

absence

PREMISES

Premises should be designed and maintained in good order To provide sufficient space to suit the activities being carried out Should allow efficient work flow Should permit effective communication and supervision Physical and non-physical working conditions:

– Ergonomics– Environmental factors– Stress

All necessary equipment for the activities to be performed efficiently should be provided – personnel should be instructed in the proper use of equipment:

– Computer hardware and software– Printers and copiers– Archives and means of communication

QUALITY ASSURANCE (QA)

A good quality management system (QMS) should be set-up by RAD for all the activities under its responsibility

QUALITY ASSURANCE

ProceduresProcedures should be laid down in writing in standard operating proceduresAuthorised by appropriate staff and communicated to the relevant personnelThis should be readily available and be checked and updated regularlySOPs should be adapted / renewed in the case of new or amended standardsSOPs should be established on how to implement relevant legislation and codes and the consequences for the organisation’s policyRAD should develop policies for situations in which changing legislation and codes make it necessary to adapt to it

QUALITY ASSURANCE

ProceduresProcedures should cover the different areas in RA to:

– Specify responsibilities and organisationo regulatory development plano development of PI and PILo preparation of CTDo compilation of dossier o change controlo preparation of response documentso maintenance of registrationo preparation of renewals, etc.

QUALITY ASSURANCE

Self-Inspection

Regular self-inspections should be performed by RAD in co-operation with QA to –

- check and ensure compliance with the relevant regulations by staff at all levels

- check the compliance with the procedures and

- adapt the procedure according to current practices

QUALITY ASSURANCE

TrainingAn initial training program should be in place for new employees to ensure a good understanding and therefore complianceAll RAD staff should be regularly trained in procedures to ensure good understanding and therefore complianceEach new procedure or update of existing procedure should also lead to a specific training on the changes implementedUnderstanding of all these aspect of the procedure should preferably be assessed by knowledge controlA tracking system of the annual training should be organized

DOCUMENTATION

Good documentation is essential for the whole organisation and especially the RAD

All documentation should be prepared with great care and clearly written to prevent errors that can arise from oral communication

DOCUMENTATION

Documents should contain all the information necessary for proper use:

– Title, type and objectives should be unambiguous and clearly stated in SOPs

– All documentation should be reviewed regularly and kept up to date

– Amendments should be dated, authorized and signed by the appropriate personnel

DOCUMENTATION

An appropriate system should be in place to:o ensure traceability of documents and their different

versionso answers to the Regulatory Authoritieso changes in PIo variations etc.

All documentation should be securely stored but readily accessible to RA personnel

When prepared or stored electronically validation processing programmes should be used

DOCUMENTATION

Data should be protected against loss or damage e.g.– Use of backup procedures– Only authorised personnel should be allowed to enter or

change data

ARCHIVING

A good archiving system is mandatory: – It should be described in a procedure – Describe, both the documentation and electronic

documents, – The archiving plan, – The management of the different versions,– The answer to questions from Regulatory Authorities, – The traceability and the measures taken to ensure regular

backup.

COMMUNICATION

Due to the multidisciplinary activities under the responsibility of RAD close relationship with almost all the departments is needed:

– Pre-clinical– Medical– Pharmacovigilance– Production– Quality Control– Quality Assurance– Marketing and sales etc

COMMUNICATION

RAD skills for communication and communicating information to other departments, Regulatory Authorities, Professional Associations

Communication - Key parameter to GRP in terms of compliance with regulatory requirements, lobbying, negotiation, effective relationship with external bodies

Checklist for Performance of RADs

Perceives disciplines and Regulators as partners, not enemies Establishes/maintains efficient contact with Regulator Works proactively Proactive in product development/maintenance teams Market orientated and customer focussed Submits dossiers of sufficiently high quality in a timely fashion

to obtain and maintain registrations Maintains a quality system

Advice

Make your mission in the organisation clear.

Make your voice heard.

You are one of the most valuable team members if allowed to live up to full capacity.

Suggested Reading

Good Drug Regulatory PracticesA Regulatory Affairs Quality Manual

Helene I. Dumitri

Over to you!

MRA Regulatory Consultants381 Rossouw Street

Murrayfield

Pretoria

Tel: +27 (0)12 803-6223

[email protected]

[email protected]

[email protected]

MEDICINE REGULATION REGULATORY DEPARTMENTS GOOD REGULATORY PRACTICE

Documents

Transcript of MEDICINE REGULATION REGULATORY DEPARTMENTS GOOD REGULATORY PRACTICE